Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)

Study Identifier
P14-152
CT.gov Identifier
NCT01960790
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Protocol
Available Language(s): English
Download document(s)
Statistical Analysis Plan
Available Language(s): English
Download document(s)
Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Immune & Inflammatory - Other
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * All patients who received Adalimumab for the treatment of Intestinal Behcet's disease (not sufficiently responsive to existing therapies, e.g. steroids, immunomodulator)
    Exclusion Criteria:
    Contraindications according to the Package Insert include patients who had any of the following: * serious infections * tuberculosis * a history of hypersensitivity to any ingredient of Humira® * demyelinating disease or a history of demyelinating disease * congestive cardiac failure

    Protocol Summary

    This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease.

    1. Incidence and conditions of occurrence of adverse reactions in clinical practice

    2. Factors likely to affect the safety and effectiveness

    Study Locations

    No locations found.